secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2024-07-16T23:59:59+00:00
Accession:  0001104659-24-080251
Event type: debt
Sentiment:  negative
Materiality: 0.70
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx enters $3.2M debt amendment with Hercules and Domicilium; Royalty obligations up to $53M
--------------------------------------------------------------------------------

- Tranche 2 Advance of $3.175M provided under Sixth Amendment to Hercules loan; Bridge Loan of $288k also made.
- Conversion options: Tranche 1A/1B debt can convert into equity if Qualified Financing ≥$7M occurs before April 2025.
- Royalty Agreement: 33% of first three Almirall milestones and 25% of subsequent milestones, capped at $53M, plus 0.75% of ELX-02 and 0.50% of ZKN-013 revenue.
- Amended Securities Purchase Agreement grants anti-dilution rights to SD MF for 15 months.
- Reporting covenant for FY2023 audited financials extended to November 29, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465924080251/0001104659-24-080251-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465924080251/tm2419633d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-080251

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer